Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 178
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Ann Hematol ; 103(4): 1131-1137, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-37428199

RESUMEN

PNS are uncommon manifestations of cancer. The current literature about these syndromes in the setting of cHL is disintegrated. A systematic literature review of all published literature was conducted. One hundred twenty-eight patients from 115 publications met the inclusion/exclusion criteria. Eight-five patients were of the NS subtype (66.4%). The most frequent clinical presentation of the PNS was CNS manifestation (25.8%). The majority of patients were diagnosed with the cHL and PNS simultaneously (42.2%). In 33.6% of patients, the lymphoma diagnosis preceded the PNS diagnosis. In 16.4% of patients, the PNS diagnosis preceded the lymphoma diagnosis. The presence of PNS antibodies was reported in 35 patients (27.3%). Age older than 18 was associated with higher prevalence of PNS. The CR rate of the lymphoma was 77.3%. The complete resolution rate of the PNS was 54.7%. Relapse of lymphoma was reported in 13 patients, and recurrence of the PNS upon relapse was reported in 10/13 patients.


Asunto(s)
Enfermedad de Hodgkin , Síndromes Paraneoplásicos del Sistema Nervioso , Síndromes Paraneoplásicos , Humanos , Síndromes Paraneoplásicos del Sistema Nervioso/diagnóstico , Enfermedad de Hodgkin/complicaciones , Recurrencia Local de Neoplasia , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/etiología , Recurrencia
2.
Medicina (Kaunas) ; 60(4)2024 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-38674198

RESUMEN

Background and Objectives: Liver cancer poses a significant global health threat, ranking among the top three causes of cancer-related deaths. Patients with hepatocellular carcinoma (HCC) often present with symptoms associated with neoplasms or unusual clinical features such as paraneoplastic syndromes (PNS), including hypoglycemia, hypercholesterolemia, thrombocytosis, and erythrocytosis. Our study aimed to investigate the prevalence, clinical characteristics, and survival outcomes associated with PNS in HCC patients and assess each PNS's impact on patient survival. Materials and Methods: We conducted a retrospective analysis of PNS clinical features and survival among consecutive HCC patients diagnosed at our department over seven years, comparing them with HCC patients without PNS. The study involved a retrospective data evaluation from 378 patients diagnosed with HCC between January 2016 and October 2023. Results: We obtained a PNS prevalence of 25.7%, with paraneoplastic hypercholesterolemia at 10.9%, hypoglycemia at 6.9%, erythrocytosis at 4.5%, and thrombocytosis at 3.4%. Patients with PNS tended to be younger and predominantly male. Multivariate analysis revealed a strong correlation between PNS and levels of alpha-fetoprotein and tumor size, with diabetes also showing a significant statistical association (p < 0.05). Subgroup analysis based on specific paraneoplastic syndromes demonstrated shorter survival in patients with PNS, albeit without significant statistical differences, except for hypoglycemia (p < 0.0001). Matched analysis indicated a shorter survival rate for patients with PNS, although no significant statistical differences were observed. Conclusions: PNS are frequently observed in HCC cases and are associated with unfavorable prognoses and decreased survival rates due to their correlation with increased tumor burdens. However, they do not independently predict poor survival. The impact of individual PNS on HCC prognosis varies.


Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Síndromes Paraneoplásicos , Humanos , Masculino , Estudios Retrospectivos , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/complicaciones , Femenino , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/mortalidad , Persona de Mediana Edad , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/complicaciones , Anciano , Prevalencia , Adulto , Análisis de Supervivencia , Hipercolesterolemia/epidemiología , Hipercolesterolemia/complicaciones , Hipoglucemia/epidemiología , Hipoglucemia/complicaciones , Policitemia/epidemiología , Policitemia/complicaciones , Anciano de 80 o más Años , Trombocitosis/epidemiología , Trombocitosis/complicaciones
3.
BMC Cancer ; 21(1): 279, 2021 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-33726691

RESUMEN

BACKGROUND: Thymic tumors are unusual neoplasms, representing 0.2 to 1.5% of tumors in humans, but correspond to 20% of mediastinal tumors and 50% of those that occur in the anterior mediastinum. They tend to appear around the fourth and fifth decades of life without gender predilection. Up to 30% of patients are asymptomatic, therefore many are incidentally diagnosed. Radical thymectomy is the treatment of choice with high survival rates when detected in the early stages. METHODS: This was a retrospective descriptive study, including 18 adult patients' diagnosis of thymic neoplasm, who were managed with surgical resection from 2011 to 2019. Information about demographics, clinical characteristics, imaging findings, surgical and medical management, plus histological findings was obtained and reported. RESULTS: 18 patients with thymic tumors were included, of which specific histologic studies reveled thymomas, carcinomas, neuroendocrine tumors, thymolipoma and thymic cyst. Mean age was 52.7 years, with a predominance of male population. The main symptom was dyspnea, followed by cough and chest pain. Paraneoplastic syndromes such as myasthenia gravis, aplastic anemia and Cushing syndrome were reported. 89% of cases were treated by radical thymectomy alone, while only 2 cases required chemotherapy and radiotherapy. There were no surgical complications. Mean hospital stay length was 11. 9 days, with only 1 mortality during hospital admission. 5-year survival rate was 81%. CONCLUSIONS: The treatment of choice is radical thymectomy, which has been shown to positively impact patient mortality. Early detection is key to improve patient outcomes.


Asunto(s)
Síndromes Paraneoplásicos/epidemiología , Timectomía , Timo/patología , Neoplasias del Timo/cirugía , Anciano , Carcinoma/complicaciones , Carcinoma/diagnóstico , Carcinoma/mortalidad , Carcinoma/cirugía , Colombia/epidemiología , Femenino , Humanos , Tiempo de Internación/estadística & datos numéricos , Lipoma/complicaciones , Lipoma/diagnóstico , Lipoma/mortalidad , Lipoma/cirugía , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/complicaciones , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/mortalidad , Tumores Neuroendocrinos/cirugía , Síndromes Paraneoplásicos/etiología , Estudios Retrospectivos , Tasa de Supervivencia , Timoma/complicaciones , Timoma/diagnóstico , Timoma/mortalidad , Timoma/cirugía , Timo/diagnóstico por imagen , Timo/cirugía , Neoplasias del Timo/complicaciones , Neoplasias del Timo/diagnóstico , Neoplasias del Timo/mortalidad
4.
J Endocrinol Invest ; 44(4): 773-780, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32725396

RESUMEN

PURPOSE: Tumor-induced osteomalacia (TIO) is an acquired form of hypophosphatemia caused by tumors with excess production of fibroblast growth factor 23 (FGF23). Some reports showed that TIO patients had renal Fanconi syndrome (FS) with unidentified mechanism. In this study, we investigated the association between genetic polymorphisms of phosphate transporters in renal proximal tubules and TIO with FS. METHODS: We recruited 30 TIO patients with FS (TIO-FS) as well as 30 TIO patients (TIO-nonFS) without any urine abnormalities matched by age and gender. We collected clinical manifestations and conducted targeted sequencing of SLC34A1, SLC34A3 and XPR1 genes and the association analysis between variants in TIO with FS and phenotypes. RESULTS: TIO-FS group had lower levels of serum phosphate (0.44 ± 0.12 vs. 0.51 ± 0.07 mmol/L, p < 0.05) than TIO-nonFS group. Among the 16 SNPs in SLC34A1, SLC34A3 and XPR1 genes, GG/GC genotypes of rs148196667 in XPR1 and AA/TA genotypes of rs35535797 in SLC34A3 were associated with a reduced susceptibility to have FS. The G allele of rs148196667 in XPR1 decreased the risk of FS. The GGAA haplotype in SLC34A3 and GCT haplotype in XPR1 were associated with a decreased risk for FS. CONCLUSIONS: The polymorphisms of XPR1 and SCL34A3 are associated with TIO patients with Fanconi syndrome. It provides novel insight to the relationship of phosphate transportation and general functions of renal proximal tubules.


Asunto(s)
Síndrome de Fanconi , Receptores Acoplados a Proteínas G/genética , Receptores Virales/genética , Proteínas Cotransportadoras de Sodio-Fosfato de Tipo IIc/genética , Adulto , China/epidemiología , Síndrome de Fanconi/epidemiología , Síndrome de Fanconi/genética , Síndrome de Fanconi/fisiopatología , Femenino , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/metabolismo , Humanos , Hipofosfatemia/diagnóstico , Hipofosfatemia/etiología , Túbulos Renales Proximales/metabolismo , Masculino , Osteomalacia/complicaciones , Osteomalacia/diagnóstico , Osteomalacia/epidemiología , Osteomalacia/metabolismo , Síndromes Paraneoplásicos/complicaciones , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/metabolismo , Fosfatos/metabolismo , Polimorfismo Genético , Receptor de Retrovirus Xenotrópico y Politrópico
5.
J Surg Oncol ; 122(2): 155-163, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32497273

RESUMEN

OBJECTIVES: To identify the association between cording and breast cancer-related lymphedema (BCRL); describe time course, location, symptoms and functional impairments. METHODS: A total of 1181 patients were prospectively screened for BCRL after breast cancer (BC) surgery, including patient-reported outcome measures (4193) and perometric arm volume measurements (BCRL defined as relative or weight-adjusted volume change [RVC or WAC] ≥10% ≥3 months postoperatively). RESULTS: A total of 374/1181 patients (31.7%) reported cording first a median of 4.5 months postoperatively, and were more likely to: have body mass index less than 30 kg/m2 ; be less than 55 years of age; have had mastectomy, axillary lymph node dissection, regional lymph node radiation, neoadjuvant chemotherapy (all P < .001), or RVC/WAC ≥10% (P = .002). Patients who reported cording had 2.4 times the odds of developing BCRL compared to those who did not (odds ratio = 2.40; 95% confidence interval = 1.40-4.11; P = .002), and most frequently reported these symptoms: tenderness (61.2%), aching (60.7%), and firmness/tightness (59.8%). On multivariable analysis, cording was significantly correlated with functional difficulty for 17 actions. CONCLUSIONS: Patients frequently present with cording, potentially months after BC surgery. Risk factors for and symptoms of cording are identified, and treatment is recommended. Patients reporting cording are at higher risk of BCRL, therefore, cording should be incorporated into BCRL risk stratification.


Asunto(s)
Linfedema del Cáncer de Mama/epidemiología , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/cirugía , Axila/patología , Linfedema del Cáncer de Mama/etiología , Linfedema del Cáncer de Mama/patología , Neoplasias de la Mama/patología , Estudios de Cohortes , Detección Precoz del Cáncer , Femenino , Humanos , Escisión del Ganglio Linfático/efectos adversos , Escisión del Ganglio Linfático/estadística & datos numéricos , Massachusetts/epidemiología , Mastectomía/efectos adversos , Mastectomía/estadística & datos numéricos , Persona de Mediana Edad , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/etiología , Síndromes Paraneoplásicos/patología , Medición de Resultados Informados por el Paciente , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/patología , Estudios Prospectivos
6.
Support Care Cancer ; 28(6): 2941-2947, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31768730

RESUMEN

PURPOSE: Breast cancer (BC) is the most common cancer in women worldwide. The main treatment for BC is surgery, which involves an axillary procedure that associates with the development of axillary web syndrome (AWS). The incidence of AWS among Chilean women with BC and its possible predisposing factors are currently unknown. Thus, we aimed to (1) determine the incidence of AWS among Chilean women with BC after surgery and (2) identify possible predisposing factors. METHODS: Within 90 days post-surgery, patients were assessed for AWS, i.e., palpable or visible axillary cords in the axillary region extending down from the mid-axilla to the ipsilateral arm. We then computed the odds ratio with 95% confidence interval (OR [95% CI]) for having AWS considering the following predisposing factors: age, body mass index (BMI), number of lymph nodes removed, axillary procedure, days from surgery to the physical therapy assessment, hospital for the surgery, type of breast surgery, and neoadyuvant chemotherapy. RESULTS: AWS was present in 49 out of 107 patients (45.8%). Younger age and lower BMI appeared as the sole predisposing factors for AWS (age, 0.95 [0.91-0.99]; BMI, normal weight 1.00, overweight 0.35 [0.11-1.12], obesity 0.28 [0.08-0.97]). CONCLUSION: The incidence of AWS among Chilean women with BC was 45.8%. Our study also confirms data from previous reports showing that younger age and low BMI are associated with the development of AWS.


Asunto(s)
Axila/patología , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/epidemiología , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/etiología , Adulto , Anciano , Índice de Masa Corporal , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Chile/epidemiología , Susceptibilidad a Enfermedades/epidemiología , Femenino , Humanos , Incidencia , Escisión del Ganglio Linfático/efectos adversos , Ganglios Linfáticos/cirugía , Mastectomía/efectos adversos , Persona de Mediana Edad , Síndromes Paraneoplásicos/patología , Factores de Riesgo
7.
Support Care Cancer ; 28(6): 2891-2898, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31754834

RESUMEN

PURPOSE: Medical treatment for head and neck cancer may induce the presence of inflammation, pain, and dysfunction. The purpose of the current study was to assess the presence of myofascial trigger points (TrPs) and their relationship with widespread pressure hypersensitivity and hyperalgesia in survivors of head and neck cancer (sHNC). METHODS: TrPs and pressure-pain thresholds (PPTs) were quantified in different muscles/joints in the head and neck of 30 sHNC (59.45 ± 13.13 years) and 28 age- and sex-matched controls (58.11 ± 12.67 years). RESULTS: The sHNC had more TrPs in all muscles on the affected side (p < 0.05) than did the healthy controls, and in the temporalis, masseter, and suboccipitalis muscles on the unaffected side (p < 0.05). They also had lower PPTs in all places (p < 0.05) except for the temporalis muscle (p = 0.114) and C5-C6 joint (p = 0.977). The intensity of cervical pain correlated positively with the presence of upper trapezius TrPs. CONCLUSIONS: sHNC suffering cervical and/or temporomandibular joint pain have multiple active TrPs and experience widespread pressure hypersensitivity and hyperalgesia, suggestive of peripheral and central sensitization.


Asunto(s)
Supervivientes de Cáncer/estadística & datos numéricos , Dolor Facial/epidemiología , Neoplasias de Cabeza y Cuello , Hiperalgesia/epidemiología , Síndromes del Dolor Miofascial/epidemiología , Dolor de Cuello/epidemiología , Dolor de Hombro/epidemiología , Adulto , Anciano , Estudios de Casos y Controles , Cara , Dolor Facial/complicaciones , Femenino , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/rehabilitación , Humanos , Hiperalgesia/complicaciones , Masculino , Persona de Mediana Edad , Síndromes del Dolor Miofascial/etiología , Dolor de Cuello/complicaciones , Umbral del Dolor , Síndromes Paraneoplásicos/epidemiología , Hombro , Dolor de Hombro/complicaciones , Puntos Disparadores
8.
Acta Derm Venereol ; 100(18): adv00312, 2020 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-33074341

RESUMEN

Paraneoplastic autoimmune multiorgan syndrome is a complex and deadly disease. We retrospectively reviewed the clinical features and risk factors for paraneoplastic autoimmune multiorgan syndrome in 145 Chinese patients. The most common neoplasm was Castleman disease (56%), and patients with Castleman disease tended to be younger (≤ 42 years old: 83% vs. 29%) and to have a greater proportions of lichen planus-like lesions (47% vs. 27%) and bronchiolitis obliterans (49% vs. 29%), compared to other neoplasm-associated patients. Among all 145 patients in the study, the survival rates were 84% at 1 year, 65% at 3 years, and 54% at 5 years. Kaplan-Meier curve analysis revealed that mortality was associated with older age (> 42 years), neoplasm type, labial lesions, and larger skin lesion area (> 17.5% of the body surface area). However, only older age and larger skin lesion area were independent factors associated with mortality in multivariate analysis. We suggest that patients with Castleman disease and paraneoplastic autoimmune multiorgan syndrome have many unique characteristics and the underlying risk factors for death require further exploration.


Asunto(s)
Síndromes Paraneoplásicos , Pénfigo , Adulto , Anciano , China/epidemiología , Humanos , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/epidemiología , Estudios Retrospectivos , Factores de Riesgo
9.
Niger J Clin Pract ; 22(9): 1271-1275, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31489865

RESUMEN

BACKGROUND: Paraneoplastic syndromes (PNS) have been defined as a constellation of symptoms and signs seen in patients with malignancy, which cannot be ascribed to the local or distant spread of the tumor. Renal cell carcinoma (RCC) is most commonly associated with PNS among urological malignancies. We describe the incidence of PNS and the association between the syndromes and oncological outcomes in our patients with RCC. SUBJECTS AND METHODS: A retrospective cohort study done at Lagos State University Teaching Hospital, Ikeja, Lagos. This was a retrospective review of our patients who had RCC over 11-year period (2006 to 2016). The incidence of PNS syndromes were hypercalcemia, Stauffer's syndrome, hypertension, anemia, elevated erythrocyte sedimentation rate (ESR), persistent leukocytosis, and its correlation to outcome of disease were analyzed. In addition, the age, gender, clinical features, and stage of disease were analyzed. Chi square, Fischer exact test, and Kaplan-Meier survival, curve and logistic regression. RESULTS: : In total, 101 patients were operated within the period. Age of the patients ranged from 11 to 81 years (mean of 45.17 ± 16.3). There were 46 males and 55 females with M:F ratio of 1:1.2. Majority of the patients, 74 (73%), had clear cell variant of RCC. Twenty-seven patients (26.7%) had triad of flank pain, flank mass, and hematuria. The incidence of PNS were hypercalcaemia 7 (6.9%), Stauffer's syndrome 12 (11.9%), hypertension 16 (15.8%), anemia 61 (60.4%), elevated ESR 56 (55.4%), and persistent leukocytosis 3 (3.0%). At a median follow-up of 6 months, 72 patients (71.3%) were alive, whereas 29 patients (28.7%) were dead. CONCLUSION: Among the PNS, only Stauffer's syndrome was significantly associated with poor outcome.


Asunto(s)
Carcinoma de Células Renales/diagnóstico , Neoplasias Renales/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Adulto , Anciano , Anemia/sangre , Sedimentación Sanguínea , Carcinoma de Células Renales/epidemiología , Carcinoma de Células Renales/patología , Femenino , Humanos , Hipertensión/complicaciones , Incidencia , Estimación de Kaplan-Meier , Neoplasias Renales/epidemiología , Neoplasias Renales/patología , Leucocitosis/sangre , Masculino , Persona de Mediana Edad , Nigeria/epidemiología , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/patología , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Síndrome
10.
J Clin Gastroenterol ; 52(7): 569-572, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29912760

RESUMEN

New-onset diabetes mellitus (DM) is one of the first symptoms of pancreatic adenocarcinoma (PDAC). The frequency of endocrine disorders is estimated between 40% and 80% in patients with pancreatic cancer. DM is a risk factor for cancer development but it may also be a consequence of the tumor growth. Data confirming the existence of a relationship between long standing type 2 DM and an increased risk of PDAC comes from numerous clinical studies. Insulin resistance phenomenon and hyperinsulinemia may result in the increased proliferation of pancreatic islets which in turn may cause a predisposition to cancer development. In contrast, it is proved that new-onset DM among patients over 50 years old significantly increases the risk of PDAC recognition. Insulin-like growth factor 1 (IGF-1) and their complex proteins, IGF binding proteins, which comprise the IGF axis play a crucial role in carbohydrate metabolism disorders and, studies have shown that they may contribute to PDAC growth. Some studies confirm that IGF-1 is connected with early carcinogenesis in animals and humans. Assessing the levels of these proteins may thus be helpful in early recognition of PDAC in patients with recently detected endocrine disorders, especially pancreatic DM.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Carcinoma Ductal Pancreático/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Proteínas de Unión a Factor de Crecimiento Similar a la Insulina/metabolismo , Factor I del Crecimiento Similar a la Insulina/metabolismo , Neoplasias Pancreáticas/metabolismo , Síndromes Paraneoplásicos/metabolismo , Receptores de Somatomedina/metabolismo , Animales , Carcinoma Ductal Pancreático/epidemiología , Carcinoma Ductal Pancreático/patología , Carcinoma Ductal Pancreático/cirugía , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/patología , Diabetes Mellitus Tipo 2/cirugía , Humanos , Mediadores de Inflamación/metabolismo , Resistencia a la Insulina , Metabolismo de los Lípidos , Pancreatectomía , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/cirugía , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/patología , Síndromes Paraneoplásicos/cirugía , Factores de Riesgo , Transducción de Señal , Resultado del Tratamiento
11.
J Am Acad Dermatol ; 79(5): 913-920.e1, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29920319

RESUMEN

BACKGROUND: Granuloma annulare (GA) is a granulomatous skin eruption rarely associated with cancer. We report seven cases of paraneoplastic GA in association with solid organ malignancy. OBJECTIVE: To compare the clinical and histopathological features of paraneoplastic GA to case-matched controls of classic GA. METHODS: Retrospective chart and histopathological review of 7 individuals and 13 age- and sex-matched controls. Paraneoplastic GA was defined as GA occurring within 6 months of the diagnosis of solid organ malignancy and/or persistent GA that resolved with cancer treatment. RESULTS: Most cases of paraneoplastic GA were associated with lung cancer (4/7). The clinical and histopathological features of paraneoplastic and classic GA were similar. Compared to classic GA, paraneoplastic GA cases were more often generalized disease (6/7 vs 6/13), refractory to treatment, and had a perivascular inflammatory cell infiltrate (5/7 vs 2/13). All cases of paraneoplastic GA that underwent definitive treatment of their cancer improved. LIMITATIONS: Single-institution, retrospective review with a small sample size. CONCLUSION: Paraneoplastic GA is rare, similar to classic GA, and refractory to treatment. We advocate for age-appropriate screening in individuals with GA that is nonresponsive to multiple lines of systemic treatment and evaluating patients with concerning signs or symptoms for an underlying neoplasm.


Asunto(s)
Transformación Celular Neoplásica/patología , Granuloma Anular/epidemiología , Granuloma Anular/patología , Neoplasias Pulmonares/epidemiología , Síndromes Paraneoplásicos/patología , Anciano , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/patología , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/patología , Estudios de Casos y Controles , Femenino , Glioblastoma/epidemiología , Glioblastoma/patología , Glioblastoma/terapia , Humanos , Incidencia , Neoplasias Pulmonares/patología , Masculino , Melanoma/epidemiología , Melanoma/patología , Melanoma/terapia , Persona de Mediana Edad , Síndromes Paraneoplásicos/epidemiología , Pronóstico , Medición de Riesgo , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/patología , Resultado del Tratamiento
12.
Reumatismo ; 70(1): 35-43, 2018 Mar 27.
Artículo en Inglés | MEDLINE | ID: mdl-29589401

RESUMEN

Polymyalgia rheumatica (PMR) is the commonest inflammatory rheumatic disease affecting older people. The current mainstay of treatment is long-term oral glucocorticoid therapy. Management of these patients in clinical practice is often complicated by the presence of comorbidity. Comorbidity might be due to shared risk factors such as age, sex, or genetic background; to the presence of the disease itself; or to adverse effects of glucocorticoid therapy. Cardiovascular disease, osteoporosis/fracture, metabolic and ocular comorbidity are of particular interest to clinicians because of their relationship to glucocorticoid therapy and the relevance to clinical treatment decisions regarding glucocorticoid tapering. Patients at high risk of exacerbation of comorbidity by glucocorticoid therapy may be considered for adjunctive steroid-sparing therapies and thus may need specialist management. From a public health perspective, with the ageing population the prevalence of PMR is predicted to increase; accurate data on comorbidity will be needed for planning and delivery of healthcare services.


Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Oftalmopatías/epidemiología , Enfermedades Metabólicas/epidemiología , Neoplasias/epidemiología , Osteoporosis/epidemiología , Polimialgia Reumática/epidemiología , Anciano , Comorbilidad , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Síndromes Paraneoplásicos/epidemiología , Polimialgia Reumática/diagnóstico , Polimialgia Reumática/tratamiento farmacológico , Prevalencia , Factores de Riesgo , Reino Unido/epidemiología
13.
Internist (Berl) ; 59(2): 114-124, 2018 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-29181551

RESUMEN

Paraneoplastic syndromes are characterized by the tumor-induced release of peptide hormones and/or the initiation of immune phenomena, which elicit clinical changes and alterations in laboratory parameters independent of the tumor size and spread. In addition to neurological, endocrinal and rheumatological phenotypes, metabolic alterations play a special role in the clinical routine as they commonly present with acute symptoms in an emergency situation and necessitate immediate diagnosis and prompt initiation of treatment. Metabolic alterations within the framework of malignant diseases should be treated in a multidisciplinary team and it is often necessary to perform monitoring and treatment in an intensive care unit. This article focuses on the diagnostic and therapeutic options for metabolic disorders due to paraneoplastic syndromes, such as hypercalcemia, hypocalcemia, hyperglycemia, hypoglycemia and a special variant of tumor-induced metabolic disorders due to tumor lysis syndrome.


Asunto(s)
Enfermedades Metabólicas/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Estudios Transversales , Diagnóstico Diferencial , Humanos , Hipercalcemia/diagnóstico , Hipercalcemia/epidemiología , Hipercalcemia/terapia , Hipoglucemia/diagnóstico , Hipoglucemia/epidemiología , Hipoglucemia/terapia , Enfermedades Metabólicas/epidemiología , Enfermedades Metabólicas/terapia , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/terapia , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/terapia , Proteína Relacionada con la Hormona Paratiroidea/sangre , Pronóstico , Factores de Riesgo , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/epidemiología , Síndrome de Lisis Tumoral/terapia
14.
Skinmed ; 15(3): 175-180, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28705276

RESUMEN

Autoimmune bullous diseases (ABDs) are uncommon but significant skin disorders with relatively high morbidity and mortality. Some surveys have been carried out to describe the spectrum of ABDs in a region, but this is the first that has focused on ABDs in elderly patients. This study was conducted to determine the clinicoepidemiologic features of ABDs in elderly patients. Medical records of all ABD patients with disease onset after the age of 60 years who presented to the Autoimmune Bullous Diseases Research Center, Tehran, Iran between April 2003 and March 2013 were reviewed. Patients with dermatitis herpetiformis were not included. During the 10-year period studied, 296 patients with ABD and disease onset after 60 years of age were diagnosed. Bullous pemphigoid (BP) was observed to be the most common ABD (48.3%), followed by pemphigus vulgaris (45.3%), pemphigus foliaceus (3.7%), mucous membrane pemphigoid (1.4%), paraneoplastic pemphigus (0.7%), epidermolysis bullosa acquisita (0.3%), and linear IgA bullous disease (0.3%). A predominance in women was observed for total ABDs, BP, and pemphigus vulgaris. Although Iran is known to have a high prevalence of pemphigus, BP is the most frequent ABD among elderly patients in Iran, highlighting the importance of the clinical diagnosis of BP in elderly patients.


Asunto(s)
Enfermedades Autoinmunes/epidemiología , Enfermedades Cutáneas Vesiculoampollosas/epidemiología , Anciano , Anciano de 80 o más Años , Estudios Transversales , Epidermólisis Ampollosa Adquirida/epidemiología , Femenino , Humanos , Irán/epidemiología , Dermatosis Bullosa IgA Lineal/epidemiología , Masculino , Persona de Mediana Edad , Síndromes Paraneoplásicos/epidemiología , Penfigoide Benigno de la Membrana Mucosa/epidemiología , Penfigoide Ampolloso/epidemiología , Pénfigo/epidemiología , Prevalencia , Estudios Retrospectivos , Factores Sexuales
15.
Actas Dermosifiliogr ; 108(10): 902-910, 2017 Dec.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28801011

RESUMEN

Paraneoplastic pemphigus (PNP), a subset of pemphigus, is a unique autoimmune blistering condition that can affect multiple organs other than the skin. It is a life-threatening disease associated with an underlying malignancy, most commonly of lymphoproliferative origin. The clinical picture may resemble pemphigus, pemphigoid, erythema multiforme, graft-versus-host disease, or lichen planus. The earliest and most consistent finding is a painful, severe, chronic and often recalcitrant stomatitis. Treatment of PNP is difficult. Immunosuppressive agents are required to decrease blistering, and treating the underlying tumor may control autoantibody production. In this review, we included essential diagnostic aspects of PNP and the most useful treatment options in the dermatologist practice.


Asunto(s)
Síndromes Paraneoplásicos/etiología , Pénfigo/etiología , Antígenos de Neoplasias/inmunología , Autoanticuerpos/biosíntesis , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Linfocitos B/inmunología , Linfocitos B/patología , Bronquiolitis Obliterante/etiología , Enfermedad de Castleman/complicaciones , Enfermedad de Castleman/inmunología , Diagnóstico Diferencial , Humanos , Inmunidad Celular , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunosupresores/uso terapéutico , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/tratamiento farmacológico , Síndromes Paraneoplásicos/epidemiología , Pénfigo/diagnóstico , Pénfigo/tratamiento farmacológico , Pénfigo/epidemiología , Pronóstico , Rituximab/uso terapéutico , Enfermedades Cutáneas Vesiculoampollosas/diagnóstico , Estomatitis/diagnóstico , Estomatitis/tratamiento farmacológico , Estomatitis/etiología
16.
J Am Acad Dermatol ; 75(3): 541-547, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27177440

RESUMEN

BACKGROUND: Paraneoplastic syndromes (PNS) are commonly associated with neuroendocrine cancers, such as small cell lung cancer. OBJECTIVES: We examined the association of PNS in Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer. METHODS: We identified PNS associated with MCC based on chart review of a Seattle-based repository and examined the incidence of MCC-associated hyponatremia in an independent cohort within Kaiser Permanente Northern California. RESULTS: Eight PNS cases were identified from the Seattle repository. Three distinct PNS types were observed: cerebellar degeneration (1 case), Lambert-Eaton myasthenic syndrome (2 cases), and malignancy-associated hyponatremia (5 cases). Moreover, the incidence of severe hyponatremia (serum sodium <125 mmol/L) coincident with MCC was identified among 4.3% (9 of 211) patients with MCC in the Kaiser Permanente Northern California cohort. LIMITATIONS: We did not have access to complete medical records on all patients so it was not possible to determine the prevalence of PNS in MCC. CONCLUSIONS: MCC can be associated with PNS similar to those found in other neuroendocrine cancers. Clinicians should be aware of these presentations as PNS often precede the identification of the underlying malignancy and usually resolve with appropriate treatment of the cancer.


Asunto(s)
Carcinoma de Células de Merkel/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/epidemiología , Neoplasias Cutáneas/diagnóstico , Distribución por Edad , Anciano , Anciano de 80 o más Años , Carcinoma de Células de Merkel/epidemiología , Carcinoma de Células de Merkel/cirugía , Comorbilidad , Supervivencia sin Enfermedad , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Síndromes Paraneoplásicos/terapia , Pronóstico , Sistema de Registros , Medición de Riesgo , Muestreo , Distribución por Sexo , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/terapia , Análisis de Supervivencia
17.
Mod Rheumatol ; 26(4): 625-9, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26391911

RESUMEN

Among about 400 patients with active arthritis and/or enthesitis who were referred to our department within the last two years, 140 of them were strongly suspected as having psoriatic arthritis by a comprehensive diagnostic procedure and after consulting specialists from dermatology, orthopedics, and radiodiagnostics at our institution and other institutions. Among them, 115 patients strictly met the classification criteria for psoriatic arthritis (CASPAR). Among the 115 patients, 19 patients (9 males and 10 females) had current psoriasis and 96 patients (22 males and 74 females) did not have current psoriasis. Nineteen (16.5%) of the 115 patients had developed malignant tumor before the onset of arthritis, and 4 (3.5%) developed malignant tumor after the onset of arthritis. Twenty-two of the 23 patients who developed malignancy were female and 10 patients developed breast cancer. Differential diagnoses in these 23 patients may include paraneoplastic syndrome. We consider that it is important to take into account the possibility of paraneoplastic syndrome in patients with arthritis and/or enthesitis who apparently meet the CASPAR criteria, and detailed screening and monitoring of malignant disease may be beneficial to the patients.


Asunto(s)
Artritis Psoriásica , Entesopatía , Neoplasias , Síndromes Paraneoplásicos , Anciano , Artritis Psoriásica/complicaciones , Artritis Psoriásica/diagnóstico , Artritis Psoriásica/epidemiología , Diagnóstico Diferencial , Detección Precoz del Cáncer/métodos , Entesopatía/diagnóstico , Entesopatía/etiología , Femenino , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Neoplasias/diagnóstico , Neoplasias/epidemiología , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/epidemiología , Gravedad del Paciente
18.
Folia Med (Plovdiv) ; 58(3): 195-199, 2016 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-27760006

RESUMEN

INTRODUCTION: Autoimmune disorders have been documented in solid tumors and malignant hematological disorders. They are very common and well studied in lymphomas which are associated with immune imbalance. They are less common in solid tumors and are categorized as paraneoplastic syndromes with unclear pathogenesis. AIM: The aim of the present study was to find the frequency of autoimmune phenomena in solid tumors of various origin, location and status of the tumor. PATIENTS AND METHODS: Between 2000 and 2014 we studied 1083 patients with solid tumors that were diagnosed and treated in St George University Hospital, Plovdiv. RESULTS: We found higher incidence of these phenomena in prostate and ovarian carcinomas (9.01% and 5.6%, respectively) than in other solid tumors. Their distribution by type of autoimmune disease showed that vasculitis, polyneuritis and autoimmune hemolytic anemia have the highest frequency of all. Immune thrombocytopenia, seronegative arthritis, psoriasis, polymyositis are less commonly documented. The autoimmune paraneoplastic phenomena manifest themselves metachronously, less commonly synchronously, with the tumor. In most cases, their clinical manifestation is a progressive disease or metastatic malignant disorder which respond favourably to therapy. CONCLUSION: Paraneoplastic autoimmune phenomena are found very commonly in prostate and ovarian carcinomas. They occur in the course of the evolvement of neoplasm and can regress with medicamentous or surgical treatment of the malignoma.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Síndromes Paraneoplásicos/inmunología , Bulgaria/epidemiología , Femenino , Humanos , Incidencia , Masculino , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/epidemiología , Prevalencia , Estudios Prospectivos
19.
Rev Med Suisse ; 12(507): 393-7, 2016 Feb 24.
Artículo en Francés | MEDLINE | ID: mdl-27039604

RESUMEN

Many conditions can lead to acute renal failure. Some of them are intrinsic renal diseases whose natural history cannot be anticipated. On the other hand, others correspond to external aggressions driven by various hemodynamic or toxic events. To some extent, these can be partially prevented by relatively simple measures. The recognition of these situations which may benefit from a preventive strategy can significantly reduce morbidity or mortality associated with the incidence of acute renal failure.


Asunto(s)
Lesión Renal Aguda/prevención & control , Servicios Preventivos de Salud/métodos , Lesión Renal Aguda/epidemiología , Lesión Renal Aguda/etiología , Medios de Contraste/efectos adversos , Humanos , Enfermedad Iatrogénica/epidemiología , Enfermedad Iatrogénica/prevención & control , Incidencia , Síndromes Paraneoplásicos/complicaciones , Síndromes Paraneoplásicos/epidemiología , Daño por Reperfusión/complicaciones , Daño por Reperfusión/epidemiología
20.
Nutr Cancer ; 67(1): 191-5, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25412019

RESUMEN

Current nutritional guidelines encourage the reduction of fat intake from animal sources like dairy products. The aim was to determine whether the consumption of low-fat dairy is related to poorer dietary intake and nutritional status in cancer patients at risk of malnutrition. This cross-sectional included patients with solid or hematological malignancies at risk of malnutrition. Nutritional status was studied using Subjective Global Assessment, anthropometry, and grip strength. Dietary intake was evaluated with a 24-h recall and dairy consumption with a structured questionnaire. Seventy-four patients were recruited; 71.6% males of 64.8 yr, most with gastrointestinal malignancies. Only 37.8% consumed whole milk, and 61.4% consumed whole yogurt. Reasons for consumption of low-fat dairies were healthy diet (58.0%), hypercholesterolemia (20.0%), and digestive intolerance (10.0%). There were similar rates of malnutrition according the type of dairy (whole 60.9% vs. low-fat 66.7%, P = 0.640). Low-fat dairies were related to a reduction in energy (whole 1980.1 kcal vs. low-fat 1480.9, P = 0.007) and protein intake (whole 86.0 g vs. low-fat 63.0 g, P = 0.030).


Asunto(s)
Productos Lácteos , Dieta con Restricción de Grasas/efectos adversos , Proteínas en la Dieta/administración & dosificación , Ingestión de Energía , Desnutrición/prevención & control , Síndromes Paraneoplásicos/prevención & control , Anciano , Animales , Estudios Transversales , Productos Lácteos/efectos adversos , Femenino , Neoplasias Gastrointestinales/fisiopatología , Hospitales Universitarios , Humanos , Masculino , Desnutrición/epidemiología , Desnutrición/etiología , Persona de Mediana Edad , Leche/efectos adversos , Política Nutricional , Servicio Ambulatorio en Hospital , Síndromes Paraneoplásicos/epidemiología , Síndromes Paraneoplásicos/etiología , Cooperación del Paciente , Riesgo , España/epidemiología , Yogur/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA